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multivariate regression analysis showed that after 
controlling for demographics, geographic regions, and
comorbidities, the average cost of informal caregivers 
for the visually impaired was almost four times as high
as that of the visually unimpaired.
CONCLUSIONS: Our study indicated that the marginal
effect of VI on costs of informal care was higher than
many other health problems commonly seen in the
elderly, such as diabetes, arthritis, urinary incontinence,
etc.
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OBJECTIVE: Retrospective analysis of administrative
claims data was performed to evaluate impact of a single
course of isotretinoin therapy on direct cost of medical
treatment for severe recalcitrant nodular acne (SRNA).
Results were compared with projections of annual cost of
conventional therapy (excluding isotretinoin). Data and
METHODS: Using the MEDSTAT Marketscan database,
we identiﬁed 475 subjects aged 12–35 who received a
single course of isotretinoin lasting 90 days or longer
from 1995–1998. Acne-related expenditures were 
calculated during isotretinoin treatment and for periods
of 12 months pre and post-isotretinoin. Direct costs
(isotretinoin, systemic/topical antibiotics, laboratory
tests, and doctor ofﬁce visits) were examined, relative 
to individual subject characteristics (gender, age, health
plan). Applying a published methodology, projections of
annual cost of conventional therapy were made by costing
an algorithm for treatment, including antibiotic and
topical therapies (Bergfeld et al., J Am Acad Dermatol
1995;32 (suppl):S52–S56).
RESULTS: On average, subjects received isotretinoin for
141 days at cost of $1231. Mean total acne-related
expenses declined from $471 (median, $311) per year
prior to isotretinoin therapy to $135 (median, $48) per
year after treatment (p < .01). More than 25% of 
subjects had no acne-related expenditures for at least 12
months post-isotretinoin. Using projections for annual
cost of conventional therapies, average total therapy-
related expenditure for isotretinoin course ($1543, year
2000 dollars) would be recouped in 8 months for treat-
ment of minocycline + topical tretinoin; with shorter time
to recoup cost with branded medications. Projections for
combination therapy of topcial tretinoin + either oral 
erythromycin or tetracycline, indicated that isotretinoin
expenditure would be recouped in 1.9 to 2.3 years.
CONCLUSION: Isotretinoin therapy substantially
reduces total acne-related direct medical expenditures 
and may result in substantial cost savings. In addition,
the comparison of expense for isotretinoin therapy with
the estimated annual cost of long-term conventional 
treatment demonstrates an opportunity for substantial
healthcare savings in the treatment of SRNA.
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OBJECTIVES: Age related macular degeneration (AMD)
is the leading cause of blindness in the United Kingdom
and the rest of the western world, occurring in 15% to
30% of those over 75 years of age. About 15% of these
patients develop a more aggressive wet form of the disease
that causes severe loss of vision.
METHODS: Costs considered are those for treatment
and social care for people with low vision. The beneﬁt
estimates come from a 2-year clinical trial of 609 patients
that compared PDT with verteporﬁn to placebo. A
Markov model was used to extrapolate the results of 
the trial to a 5-year time horizon. Transition rates in 
the model were based on a time-to-event analysis using a
Weibull parametric hazard, with the assumption that the
treated eye is the better seeing eye. Two outcomes were
measured, vision years gained and quality adjusted life
years (QALYs) gained.
RESULTS: The cost per vision year gained estimates
range from £13,000 to £15,000 over 2 years, while those
modeled to 5 years range from £5,000 to £9,000. The
cost per QALY gained within the trial time frame range
from £58,000 to £66,000, and is estimated to range from
£22,000 to £43,000 at 5 years. Earlier intervention has
greater expected cost effectiveness in the long term, in
spite of more treatments being given overall. For example,
with a 5-year follow-up, starting a treatment cohort 
at 20/40 yields an expected cost per QALY of £22,000–
£30,000, but starting a cohort at 20/100 yields an
expected cost per QALY of £34,000–£43,000. The main
driver in the costs for the treatment group is the cost of
therapy, and these costs are estimated to occur mainly in
the ﬁrst 2 years.
CONCLUSION: Early intervention may yield acceptable
cost-effectiveness levels. Consideration should be given to
early detection and treatment of people with AMD.
